RTP Mobile Logo
Acute Leukemias Update, Issue 1, 2019 (Video Program)
Released April 2019

Featuring interviews with Drs Mark Levis and Farhad Ravandi. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, hematologists-oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hematologic cancers.

    The treatment of acute leukemias remains a challenge for many healthcare professionals and patients despite recent gains made in the management of this group of diseases. Determining which approach is most appropriate requires careful consideration of patient and disease characteristics, physician expertise and available health-system resources. Published results from ongoing trials continually lead to the emergence of new therapeutic targets and regimens, thereby altering management algorithms. In order to offer optimal patient care, including the option of clinical trial participation, the practicing medical oncologist must be well informed of these advances.

    To bridge the gap between research and patient care, this issue of Acute Leukemias Update features one-on-one discussions with leading hematology-oncology investigators. By providing information on the latest clinical developments in the context of expert perspectives, this CME activity assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of evidence-based and current therapeutic strategies.


    • Appraise current data on recent therapeutic advances and changing practice standards, including FDA approvals, in acute forms of leukemia, and integrate this information into clinical care.
    • Recognize the clinical and prognostic significance of specific cytogenetic and molecular abnormalities, and use this information to refine diagnostic algorithms for acute myeloid leukemia (AML).
    • Consider patient age, performance status and other disease-related factors in the selection and sequencing of therapy for AML.
    • Understand the biologic rationale for and early efficacy and toxicity data with the use of chimeric antigen receptor-directed T-cell therapy for patients with relapsed acute lymphoblastic leukemia, and, where appropriate, facilitate patient access to this approach.
    • Identify the mechanisms of action, efficacy and side effects of newly approved and investigational agents demonstrating promising activity in acute forms of leukemia, and refer appropriately selected patients for participation in clinical trials evaluating these approaches.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Mark Levis, MD, PhD
    Director, Adult Leukemia Program
    Co-Division Director, Hematologic Malignancies
    Professor of Oncology
    The Sidney Kimmel Comprehensive Cancer Center
    Johns Hopkins University
    Baltimore, Maryland

    Advisory Committee: Agios Pharmaceuticals Inc, Amgen Inc, Astellas Pharma Global Development Inc, Daiichi Sankyo Inc, FUJIFILM Pharmaceuticals USA Inc, Novartis; Contracted Research: Astellas Pharma Global Development Inc, FUJIFILM Pharmaceuticals USA Inc, Novartis; Data and Safety Monitoring Board/Committee: Axios Pharma.

    Farhad Ravandi, MD
    Janiece and Stephen A Lasher Professor of Medicine
    Chief, Section of Developmental Therapeutics
    Department of Leukemia
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee: Amgen Inc, Astellas Pharma Global Development Inc, Bristol-Myers Squibb Company, Jazz Pharmaceuticals Inc, MacroGenics Inc, Orsenix, Seattle Genetics, Xencor; Consulting Agreements: Amgen Inc, Astellas Pharma Global Development Inc, Bristol-Myers Squibb Company, Jazz Pharmaceuticals Inc, Orsenix, Seattle Genetics, Xencor; Contracted Research: Amgen Inc, Bristol-Myers Squibb Company, Jazz Pharmaceuticals Inc, Orsenix, Xencor.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Amgen Inc, Astellas Pharma Global Development Inc, Celgene Corporation, Daiichi Sankyo Inc, Genentech, Novartis and Takeda Oncology.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: April 2019
    Expiration date: April 2020

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):

Interview with Mark Levis, MD, PhD

Interview with Farhad Ravandi, MD

Select Publications